Literature DB >> 16192781

Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials.

Jan-Uwe Schreiber1, Christopher Lysakowski, Thomas Fuchs-Buder, Martin R Tramèr.   

Abstract

Fifty-two randomized trials (5,318 patients) were included in this meta-analysis. In controls, the incidence of fasciculation was 95%, and the incidence of myalgia at 24 h was 50%. Nondepolarizing muscle relaxants, lidocaine, or magnesium prevented fasciculation (number needed to treat, 1.2-2.5). Best prevention of myalgia was with nonsteroidal antiinflammatory drugs (number needed to treat, 2.5) and with rocuronium or lidocaine (number needed to treat, 3). There was a dose-dependent risk of blurred vision, diplopia, voice disorders, and difficulty in breathing and swallowing (number needed to harm, < 3.5) with muscle relaxants. There was evidence of less myalgia with 1.5 mg/kg succinylcholine (compared with 1 mg/kg). Opioids had no impact. Succinylcholine-induced fasciculation may best be prevented with muscle relaxants, lidocaine, or magnesium. Myalgia may best be prevented with muscle relaxants, lidocaine, or nonsteroidal antiinflammatory drugs. The risk of potentially serious adverse events with muscle relaxants is not negligible. Data that allow for a risk-benefit assessment are lacking for other drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192781     DOI: 10.1097/00000542-200510000-00027

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  23 in total

1.  [Muscle relaxants in Germany 2005: a comparison of application customs in hospitals and private practices].

Authors:  H Fink; G Geldner; T Fuchs-Buder; R Hofmockel; K Ulm; B Wallek; M Blobner
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

Review 2.  [Neuromuscular blockades. Agents, monitoring and antagonism].

Authors:  J-U Schreiber; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

Review 3.  Rocuronium versus succinylcholine for rapid sequence induction intubation.

Authors:  Diem T T Tran; Ethan K Newton; Victoria A H Mount; Jacques S Lee; George A Wells; Jeffrey J Perry
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29

4.  Recurrent Laryngeal Nerve Monitoring and Rocuronium: A Selective Sugammadex Reversal Protocol.

Authors:  Ombeline Empis de Vendin; Denis Schmartz; Laurent Brunaud; Thomas Fuchs-Buder
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

5.  Local warming at injection site helps alleviate pain after rocuronium administration.

Authors:  Charu Mahajan; Girija Prasad Rath; Parmod Kumar Bithal; Hemanshu Prabhakar; Rahul Yadav; Surya Kumar Dube
Journal:  J Anesth       Date:  2010-08-25       Impact factor: 2.078

6.  Effect of landiolol hydrochloride on suxamethonium-induced neuromuscular block.

Authors:  Takahiro Suzuki; Mayu Aono; Tomomi Isaka; Eri Miyake; Naoko Fukano; Shigeru Saeki; Setsuro Ogawa
Journal:  J Anesth       Date:  2009-05-15       Impact factor: 2.078

7.  Remifentanil attenuates muscle fasciculations by succinylcholine.

Authors:  Mi Ja Yun; Yoon Hee Kim; Young Kwon Go; Ji Eun Shin; Choon Gun Ryu; Won Kim; Nam Jong Paik; Moon Ku Han; Sang Hwan Do; Woo Suk Jung
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

8.  Effect of nitrous oxide on pain due to rocuronium injection: A randomised, double-blind, controlled clinical trial.

Authors:  Sonal Sharma; Deepak Sharma; Ashish Jain; Anjali Jain
Journal:  Indian J Anaesth       Date:  2010-03

9.  Use of Succinylcholine by Anaesthetists in Turkey: A National Survey.

Authors:  Dilek Ömür; Hasan Ali Kiraz; Hasan Şahin; Hüseyin Toman; Berna Uyan; Serpil Ekin; Volkan Hancı
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

10.  Succinylcholine: the dilemma with the evidence: comment on: Tejirian T, Lewis CE, Conner J et al. Succinylcholine: a drug to avoid in bariatric surgery. Obes Surg 2009; 19: 534-6.

Authors:  Jan-Uwe Schreiber; Thomas Fuchs-Buder
Journal:  Obes Surg       Date:  2009-10-14       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.